Therapy Name | Vemurafenib + Cetuximab + Irinotecan |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cetuximab | Erbitux | EGFR Antibody 27 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). | |
Irinotecan | Camptosar | CPT-11|Onivyde | TOPO1 inhibitor 7 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death (NCI Drug Dictionary). Camptosar (irinotecan) is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Vemurafenib | Zelboraf | RO5185426|PLX4032 | RAF Inhibitor (Pan) 17 | Zelboraf (vemurafenib) inhibits BRAF V600E, wild-type BRAF, ARAF, and CRAF (PMID: 20179705), which may result in an inhibition of the MAPK signaling pathway resulting in a reduction of tumor cell proliferation (PMID: 20823850). Zelboraf (vemurafenib) is FDA approved for BRAF V600E-mutant melanoma and for BRAF V600-positive Erdheim-Chester disease (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | BRAF V600E | rectum cancer | sensitive | Vemurafenib + Cetuximab + Irinotecan | Guideline | Actionable | Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org). | detail... | BRAF V600E | colon cancer | sensitive | Vemurafenib + Cetuximab + Irinotecan | Guideline | Actionable | Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org). | detail... | BRAF V600X | colorectal cancer | sensitive | Vemurafenib + Cetuximab + Irinotecan | Phase Ib/II | Actionable | In a Phase Ib trial, the addition of Zelboraf (vemurafenib) to Camptosar (irinotecan) plus Erbitux (cetuximab) improved progression-free survival (4.4 mo vs. 2.0 mo), and disease control rate (67% vs. 22%), compared to Camptosar (irinotecan) plus Erbitux (cetuximab) without Zelboraf (vemurafenib), in patients with BRAF V600-mutant colorectal cancer (J Clin Oncol 35, 2017 (suppl 4S; abstract 520)). | detail... |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT01787500 | Phase I | Vemurafenib + Cetuximab + Irinotecan | Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers | Active, not recruiting |
NCT02164916 | Phase II | Cetuximab + Irinotecan Vemurafenib + Cetuximab + Irinotecan | S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | Active, not recruiting |